Comparing the efficacy and safety of Crocus sativus L. with memantine in patients with moderate to severe Alzheimer's disease: A double-blind randomized clinical trial

Human Psychopharmacology

Volumn 29, Issue 4, 2014, Pages 351-359

  Farokhnia, Mehdi ^a   Shafiee Sabet, Mehdi ^a   Iranpour, Negar ^a   Gougol, Amirhossein ^a   Yekehtaz, Habibeh ^a   Alimardani, Roozbeh ^a   Farsad, Farzaneh ^a   Kamalipour, Maryam ^a   Akhondzadeh, Shahin ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Alzheimer's disease; Crocus sativus L.; glutamate; memantine; saffron

Indexed keywords

CROCUS SATIVUS EXTRACT; MEMANTINE; PLANT EXTRACT;

AGED; AGITATION; ALZHEIMER DISEASE; ARTICLE; CONFUSION; CONTROLLED STUDY; CROCUS SATIVUS; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT STAGING; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DETERIORATION; MENTAL HEALTH; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA AND VOMITING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; SEVERE COGNITIVE IMPAIRMENT RATING SCALE; SIDE EFFECT; TREATMENT OUTCOME; XEROSTOMIA; COMPARATIVE STUDY; CROCUS; IRAN; PHYTOTHERAPY; PSYCHOLOGICAL RATING SCALE;

AGED; ALZHEIMER DISEASE; CROCUS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IRAN; MALE; MEMANTINE; PHYTOTHERAPY; PLANT EXTRACTS; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 84904001868     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2412     Document Type: Article

References (52)

1. Abe K, Saito H,. 2000. Effects of saffron extract and its constituent crocin on learning behaviour and long-term potentiation. Phytother Res 14: 149-152.
2. Ahn JH, Hu Y, Hernandez M, Kim JR,. 2011. Crocetin inhibits beta-amyloid fibrillization and stabilizes beta-amyloid oligomers. Biochem Biophys Res Commun 414: 79-83.
3. Akhondzadeh S, Abbasi SH,. 2006. Herbal medicine in the treatment of Alzheimer's disease. Am J Alzheimers Dis Other Demen 21: 113-118.
4. Akhondzadeh Basti A, Moshiri E, Noorbala AA, Jamshidi AH, Abbasi SH, Akhondzadeh S,. 2007. Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 31: 439-442.
5. Akhondzadeh S, Fallah-Pour H, Afkham K, Jamshidi AH, Khalighi-Cigaroudi F,. 2004. Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial [ISRCTN45683816]. BMC Complement Altern Med 4: 12.
6. Akhondzadeh S, Tahmacebi-Pour N, Noorbala AA, et al,. 2005. Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial. Phytother Res 19: 148-151.
7. Akhondzadeh S, Sabet MS, Harirchian MH, et al,. 2010a. Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial. J Clin Pharm Ther 35: 581-588.
8. Akhondzadeh S, Shafiee Sabet M, Harirchian MH, et al,. 2010b. A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer's disease. Psychopharmacology (Berl) 207: 637-643.
9. Auer SR, Sclan SG, Yaffee RA, Reisberg B,. 1994. The neglected half of Alzheimer disease: cognitive and functional concomitants of severe dementia. J Am Geriatr Soc 42: 1266-1272.
10. Ballard C, Day S, Sharp S, Wing G, Sorensen S,. 2008. Neuropsychiatric symptoms in dementia: importance and treatment considerations. Int Rev Psychiatry 20: 396-404.
11. Berger F, Hensel A, Nieber K,. 2011. Saffron extract and trans-crocetin inhibit glutamatergic synaptic transmission in rat cortical brain slices. Neuroscience 180: 238-247.
12. Choe JY, Youn JC, Park JH, et al,. 2008. The Severe Cognitive Impairment Rating Scale-an instrument for the assessment of cognition in moderate to severe dementia patients. Dement Geriatr Cogn Disord 25: 321-328.
13. Chopra K, Misra S, Kuhad A,. 2011. Neurobiological aspects of Alzheimer's disease. Expert Opin Ther Targets 15: 535-555.
14. Cummings JL, Cole G,. 2002. Alzheimer disease. JAMA 287: 2335-2338.
15. Folstein MF, Robins LN, Helzer JE,. 1983. The Mini-Mental State Examination. Arch Gen Psychiatry 40: 812.
16. Forchetti CM,. 2005. Treating patients with moderate to severe Alzheimer's disease: implications of recent pharmacologic studies. Prim Care Companion J Clin Psychiatry 7: 155-161.
17. Geromichalos GD, Lamari FN, Papandreou MA, et al,. 2012. Saffron as a source of novel acetylcholinesterase inhibitors: molecular docking and in vitro enzymatic studies. J Agric Food Chem 60: 6131-6138.
18. Ghadrdoost B, Vafaei AA, Rashidy-Pour A, et al,. 2011. Protective effects of saffron extract and its active constituent crocin against oxidative stress and spatial learning and memory deficits induced by chronic stress in rats. Eur J Pharmacol 667: 222-229.
19. Grossberg GT, Manes F, Allegri RF, et al,. 2013. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs 27: 469-478.
20. Herrmann N, Gauthier S,. 2008. Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease. CMAJ 179: 1279-1287.
21. Hosseinzadeh H, Sadeghnia HR, Rahimi A,. 2008. Effect of safranal on extracellular hippocampal levels of glutamate and aspartate during kainic Acid treatment in anesthetized rats. Planta Med 74: 1441-1445.
22. Hsiung GY, Feldman HH,. 2008. Pharmacological treatment in moderate-to-severe Alzheimer's disease. Expert Opin Pharmacother 9: 2575-2582.
23. Johnson DK, Watts AS, Chapin BA, Anderson R, Burns JM,. 2011. Neuropsychiatric profiles in dementia. Alzheimer Dis Assoc Disord 25: 326-332.
24. Kamalipour M, Akhondzadeh S,. 2011. Cardiovascular effects of saffron: an evidence-based review. J Tehran Heart Cent 6: 59-61.
25. Kennedy DO, Wightman EL,. 2011. Herbal extracts and phytochemicals: plant secondary metabolites and the enhancement of human brain function. Adv Nutr 2: 32-50.
26. Kumar V,. 2006. Potential medicinal plants for CNS disorders: an overview. Phytother Res 20: 1023-1035.
27. Lee HB, Lyketsos CG,. 2003. Depression in Alzheimer's disease: heterogeneity and related issues. Biol Psychiatry 54: 353-362.
28. Mckhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM,. 1984. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944.
29. Melnyk JP, Wang S, Marcone MF,. 2010. Chemical and biological properties of the world's most expensive spice: saffron. Food Res Int 43: 1981-1989.
30. Modabbernia A, Akhondzadeh S,. 2013. Saffron, passionflower, valerian and sage for mental health. Psychiatr Clin North Am 36: 85-91.
31. Modaghegh MH, Shahabian M, Esmaeili HA, Rajbai O, Hosseinzadeh H,. 2008. Safety evaluation of saffron (Crocus sativus) tablets in healthy volunteers. Phytomedicine 15: 1032-1037.
32. Montoro P, Maldini M, Luciani L, Tuberoso CI, Congiu F, Pizza C,. 2012. Radical scavenging activity and LC-MS metabolic profiling of petals, stamens, and flowers of Crocus sativus L. J Food Sci 77: C893-C900.
33. Moreira PI, Siedlak SL, Aliev G, et al,. 2005. Oxidative stress mechanisms and potential therapeutics in Alzheimer disease. J Neural Transm 112: 921-932.
34. Moshiri E, Basti AA, Noorbala AA, et al,. 2006. Crocus sativus L. (petal) in the treatment of mild-to-moderate depression: a double-blind, randomized and placebo-controlled trial. Phytomedicine 13: 607-611.
35. Noorbala AA, Akhondzadeh S, Tahmacebi-Pour N, Jamshidi A. H. 2005. Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial. J Ethnopharmacol 97: 281-284.
36. Ochiai T, Shimeno H, Mishima K, Iwasaki K, et al,. 2007. Protective effects of carotenoids from saffron on neuronal injury in vitro and in vivo. Biochim Biophys Acta 1770: 578-584.
37. Ohno Y, Nakanishi T, Umigai N, Tsuruma K, Shimazawa M, Hara H,. 2012. Oral administration of crocetin prevents inner retinal damage induced by N-methyl- d -aspartate in mice. Eur J Pharmacol 690: 84-89.
38. Papandreou MA, Kanakis CD, Polissiou MG, et al,. 2006. Inhibitory activity on amyloid-beta aggregation and antioxidant properties of Crocus sativus stigmas extract and its crocin constituents. J Agric Food Chem 54: 8762-8768.
39. Papandreou MA, Tsachaki M, Efthimiopoulos S, Cordopatis P, Lamari FN, Margarity M,. 2011. Memory enhancing effects of saffron in aged mice are correlated with antioxidant protection. Behav Brain Res 219: 197-204.
40. Pitsikas N, Sakellaridis N,. 2006. Crocus sativus L. extracts antagonize memory impairments in different behavioural tasks in the rat. Behav Brain Res 173: 112-115.
41. Pitsikas N, Zisopoulou S, Tarantilis PA, Kanakis CD, Polissiou MG, Sakellaridis N,. 2007. Effects of the active constituents of Crocus sativus L., crocins on recognition and spatial rats' memory. Behav Brain Res 183: 141-146.
42. Prasansuklab A, Tencomnao T,. 2013. Amyloidosis in Alzheimer's disease: the toxicity of amyloid beta (A beta), mechanisms of its accumulation and implications of medicinal plants for therapy. Evid Based Complement Alternat Med 2013: 413808.
43. Revett TJ, Baker GB, Jhamandas J, Kar S,. 2013. Glutamate system, amyloid ss peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology. J Psychiatry Neurosci 38: 6-23.
44. Riederer P, Hoyer S,. 2006. From benefit to damage. Glutamate and advanced glycation end products in Alzheimer brain. J Neural Transm 113: 1671-1677.
45. Schmidt M, Betti G, Hensel A,. 2007. Saffron in phytotherapy: pharmacology and clinical uses. Wien Med Wochenschr 157: 315-319.
46. Schneider LS, Dagerman KS, Higgins JP, Mcshane R,. 2011. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol 68: 991-998.
47. Sclan SG, Reisberg B,. 1992. Functional assessment staging (FAST) in Alzheimer's disease: reliability, validity, and ordinality. Int Psychogeriatr 4 (Suppl 1): 55-69.
48. Serrano-Diaz J, Sanchez AM, Maggi L, et al,. 2012. Increasing the applications of Crocus sativus flowers as natural antioxidants. J Food Sci 77: C1162-C1168.
49. Srivastava R, Ahmed H, Dixit RK, Dharamveer, Saraf SA,. 2010. Crocus sativus L.: a comprehensive review. Pharmacogn Rev 4: 200-208.
50. Ulbricht C, Conquer J, Costa D, et al,. 2011. An evidence-based systematic review of saffron (Crocus sativus) by the Natural Standard Research Collaboration. J Diet Suppl 8: 58-114.
51. Zhang Y, Shoyama Y, Sugiura M, Saito H,. 1994. Effects of Crocus sativus L. on the ethanol-induced impairment of passive avoidance performances in mice. Biol Pharm Bull 17: 217-221.
52. Zhao Y, Kuo T-C, Weir S, Kramer MS, Ash AS,. 2008. Healthcare costs and utilization for Medicare beneficiaries with Alzheimer's. BMC Health Serv Res 8: 108.